Artemisinin-based combination therapy for ... - The Cochrane Library

5.1 Mean haemoglobin (g/dl)
at baseline
5.2 Mean change in
haemoglobin (g/dl) from
baseline to day 14
5.3 Mean change in
haemoglobin (g/dl) from
baseline to Day 28
5.4 Mean haemoglobin (g/dl)
at Day 28
6 Serious adverse events (including
deaths)
4 Mean Difference (IV, Fixed, 95% CI) Not estimable
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
2 Mean Difference (IV, Fixed, 95% CI) Not estimable
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
7 4200 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.36, 1.03]
Comparison 14. Dihydroartemisinin-piperaquine dose analysis: 3 dose vs 4 dose regimen
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total Failure PCR unadjusted 1 318 Risk Ratio (M-H, Fixed, 95% CI) 1.72 [0.84, 3.53]
1.1 Day 63 1 318 Risk Ratio (M-H, Fixed, 95% CI) 1.72 [0.84, 3.53]
2 Total Failure PCR adjusted 1 292 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.05, 6.09]
2.1 Day 63 1 292 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.05, 6.09]
Comparison 15. Dihydroartemisinin-piperaquine dose analysis (versus Artesunate plus mefloquine)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total Failure Day 63 PCR
unadjusted
4 1784 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.49, 1.38]
1.1 DHA-P 4 doses 3 1019 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.59, 1.10]
1.2 DHA-P 3 doses 2 765 Risk Ratio (M-H, Random, 95% CI) 1.44 [0.09, 22.81]
2 Total Failure Day 63 PCR
adjusted
4 1634 Risk Ratio (M-H, Random, 95% CI) 0.48 [0.18, 1.31]
2.1 DHA-P 4 doses 3 908 Risk Ratio (M-H, Random, 95% CI) 0.42 [0.17, 1.04]
2.2 DHA-P 3 doses 2 726 Risk Ratio (M-H, Random, 95% CI) 1.27 [0.03, 48.28]
3 Total Failure Day 42 PCR
unadjusted
5 2126 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.43, 1.35]
3.1 DHA-P 4 doses 3 957 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.50, 1.28]
3.2 DHA-P 3 doses 3 1169 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.20, 3.81]
4 Total Failure Day 42 PCR
adjusted
5 2043 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.20, 1.91]
4.1 DHA-P 4 doses 3 903 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.14, 2.82]
4.2 DHA-P 3 doses 3 1140 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.08, 5.87]
5 Total Failure Day 28 PCR
unadjusted
6 2191 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.20, 2.65]
5.1 DHA-P 4 doses 4 1075 Risk Ratio (M-H, Random, 95% CI) 0.56 [0.10, 3.14]
Artemisinin-based combination therapy for treating uncomplicated malaria (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
120